RCT | Safety and efficacy of rituximab vs. dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome.

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial – The Lancet Neurology (link to abstract – $ for full-text)

News Release: Fewer relapses in MS with off-label drug – Karolinska Institutet